Compare GSK plc (GSK) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? GSK plc trades at $46.55 (market cap $91.88B), while Vanguard Total Stock Market Index Fund ETF trades at $382.2 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 25× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| GSK | VTI | |
|---|---|---|
Market Cap | $91.88B | $2.30T |
Volume | 7,730,529 | 2,982,924 |
Sector | Health | — |
52-Week High | $61.18 | $384.30 |
52-Week Low | $43.24 | $311.68 |
Typical Hold Time | 93 Days | 131 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VTI trades at $381.82, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest and broad diversification across the U.S. stock market. Recent news highlights its long-term growth potential and cost efficiency, with a dividend scheduled for September 2026.
The outlook for VTI remains positive due to its low-cost structure and exposure to the entire U.S. equity market. Risks include concentration in top holdings and market volatility, but its historical performance supports a solid foundation for long-term investors seeking diversified growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
